Close menu




Biotechnology

Photo credits: pixabay.com

Commented by Stefan Feulner on May 23rd, 2022 | 13:01 CEST

BioNTech, Monkeypox, Defence Therapeutics, Valneva - Is the next threat coming after Corona?

  • Biotechnology
  • Monkeypox

The Corona pandemic is not over yet, but we should already prepare for future viruses. The next pandemic will come. When it will come is uncertain, and so is which pathogen will we have to deal with. Monkeypox is now spreading globally, and there are already the first cases in Germany. We find out what is known so far, where the dangers lie and what opportunities there are for the biotechnology sector from Dr Moutih Rafei, a renowned pharmacologist and head of research and development at the innovative company Defence Therapeutics Inc.

Read

Commented by Fabian Lorenz on May 19th, 2022 | 13:31 CEST

Booster for the BioNTech share: BASF and Defense Metals with momentum?

  • RareEarths
  • Biotechnology

The swing market continues to keep investors on their toes. On Tuesday, encouraging economic data and the prospect of an imminent end to the lockdowns in China ensured a good mood and significantly rising prices. The speech by Fed Chairman Powell could not change this. Only one day later, the euphoria has already faded, and the statements of the central bank chief are being interpreted negatively. Powell had reiterated the Fed's determination to fight inflation. Therefore, operational impulses are needed for shares to rise again. BioNTech's stock got a small boost from the FDA's approval of its Corona vaccine as a booster shot for ages 5-11. But analysts are waiting for more. At Defense Metals, investors hope for more from today's CEO presentation after solid drilling results. At BASF, several analysts are reducing price targets at once and see possible additional costs in the billions.

Read

Commented by André Will-Laudien on May 18th, 2022 | 12:48 CEST

Biotech stocks: BioNTech, XPhyto Therapeutics, Novavax, Valneva - Crashing, the choice remains difficult!

  • Biotechnology
  • Covid19

For pure play vaccine companies, the environment is getting tougher. On the one hand, the winter is over, and on the other, Corona has lost its horrors, especially as the Omicron variant presented like a cold for most infected people. 77.6% of the German population have received at least one vaccination dose so far. 63.1 million people have thus already received basic immunization, and 49.5 million people went for another shot. Only 4.6 million people, or 5.5%, have already received a second booster vaccination. 18.6 million people have not been vaccinated, or 22.4% of the population. With currently only 4,000 vaccinations per day, the many millions of vaccine doses ordered are likely to remain on the shelf. For vaccine manufacturers, future orders will plummet. Which Company has a plan B in place?

Read

Commented by Juliane Zielonka on May 12th, 2022 | 13:07 CEST

Cardiol Therapeutics, Tesla, Bayer AG - Instead of trading chronically overvalued shares, treat the chronically ill instead

  • Biotechnology

No sooner does the US government under Biden seek to influence the Supreme Court in the Monsanto case than the Bayer share slides 7%. But is this share price slide justified? Bayer AG has made provisions for the possible ruling in June and set aside reserves for chronic diseases. Chronic diseases are also a focus of Cardiol Therapeutics. According to the World Health Organization (WHO), the prevalence of chronic diseases increased by 57% worldwide by 2020. Cardiol focuses on heart health in this regard. The share stands at about EUR 1.12 and is seen by analysts at an average of about EUR 7. Meanwhile, Tesla investors are currently experiencing what overvalued shares can do to their portfolios. Their CEO is speculating that he will no longer accept new customers. Why? You can read about it here...

Read

Commented by Fabian Lorenz on May 12th, 2022 | 11:12 CEST

BioNTech, BYD and Desert Gold: Shares for the rebound

  • Gold
  • Electromobility
  • Biotechnology

Is the rebound coming? After the heavy price losses of recent days and weeks, the market seems ripe for a countermovement. However, this would require a little more volume in the market. But then, especially companies that have not disappointed operationally should profit. BioNTech, for example, belongs to this group. The Company has published convincing figures, and analysts see up to 50% price potential. BYD's share price should also pick up speed again. Finally, the rapid shift to electric pureplay seems to be succeeding and HSBC has raised the price target. Gold was not a safe haven in the current correction. But it is worth looking at bombed-out stocks here as well. Desert Gold Ventures is one of them. The explorer has started a new drill program and secured financing.

Read

Commented by Juliane Zielonka on May 10th, 2022 | 12:38 CEST

Biotech stocks: Defence Therapeutics, BioNTech, BASF - Advantage through platform technology

  • Biotechnology

Large corporations such as BASF were previously considered safe portfolio investments. But the war in Ukraine is throwing a spanner in the works. Force majeure, such as war, can cause deals to fall through without the responsibility of the companies involved. How should investors react now? Which portfolio strategy can keep up with the high volatility of the markets? Newcomers like BioNTech face oversupply and have to accept shortages. A focus on emerging markets seems to be the solution for their growth strategy. But there are subtle differences in the vaccines business, as Defence Therapeutics proves.

Read

Commented by Juliane Zielonka on May 5th, 2022 | 12:57 CEST

Bayer, NervGen, Adler Group - Pharma and Real Estate, management in focus

  • Biotechnology
  • Pharma
  • Investments

Corporate giant Bayer is collaborating with Charité Berlin to cure genetic diseases in the future. A paradox? Big Pharma thrives on alleviating symptoms but not curing diseases. Things will soon look different. The biotech company NervGen is also dedicated to curing diseases. The approach here: reverse degenerative nerve conditions through self-healing. Specifically, this means helping individuals with paraplegia who are wheelchair-bound reconnect their neural pathways. The Company is in the clinical trials phase and was started by a co-founder who witnessed a dramatic accident. One cannot speak of an accident at the real estate company Adler Group. Four board members have resigned after auditor KPMG refused to give its OK for the annual financial statements. Can management regain the confidence of shareholders?

Read

Commented by Nico Popp on May 5th, 2022 | 11:52 CEST

Biotech-Investments also work conservatively: BioNTech, XPhyto, Valneva

  • Biotechnology
  • Pharma
  • Covid19

Biotech stocks are often seen as all-or-nothing investments - either a bet works out, or the companies disappear into oblivion. But innovative companies in the pharmaceutical and biotech sectors do not always operate in just one area. They are not always spectacular projects that are dependent on approval procedures. We outline the investment opportunities around three well-known biotech stocks.

Read

Commented by Fabian Lorenz on May 3rd, 2022 | 11:48 CEST

BYD and Altech with strong news: Hope for BioNTech shares?

  • Technology
  • Electromobility
  • Biotechnology

Rising interest rates, the war in Ukraine, lockdowns in China and recession fears: the current global mix is not conducive to rising share prices, but there is also positive news from companies. Among them is BYD. The largest Chinese manufacturer of electric cars has published quarterly figures and thus convinced analysts. In addition, BYD is celebrating the delivery anniversary of its flagship. The share of Altech Advanced Materials is also currently stepping on the gas. A study has confirmed that the planned production plant of the Heidelberg-based Company can be highly profitable. With the plant, Altech wants to stir up the market for lithium-ion batteries. BioNTech shareholders are still waiting for positive news - but there is hope.

Read

Commented by André Will-Laudien on May 2nd, 2022 | 13:27 CEST

BioNTech, Defence Therapeutics, Valneva, MorphoSys - Biotech stocks that will still be fun tomorrow!

  • Biotechnology

One of the most churned areas on the growth stock market is the biotech sector. There was too much disappointment on the drug development side; even in the COVID sector, only a few winners remain. However, the current sell-off could turn out to be an entry opportunity in the medium term because there are more and more people on earth and, fortunately, they are getting older and older; even the Corona pandemic is not likely to change this. There are already 1 billion people worldwide over the age of 60, and forecasts predict that this figure will rise to 2 billion by 2050 - with a total population of more than 9 billion people predicted at that time. Which values have been unjustly neglected, and where are the current opportunities for investors?

Read